Merck, Incyte test potential first-line Keytruda combo; Mylan, Perrigo clash over Israeli listing;

@FiercePharma: Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article | Follow @CarlyHFierce

> Merck ($MRK) and Incyte ($INCY) have expanded their clinical trial collaboration to include a Phase III study combining Merck's Keytruda with Incyte's epacadostat as a first-line treatment for advanced melanoma. Release

> Mylan ($MYL) says it has no obligation to publish a prospectus in Israel for its takeover bid just because Perrigo ($PRGO) is listed on the country's stock exchange. Report

> Helsinn Healthcare and Dr. Reddy's Laboratories ($RDY) have entered into a settlement to resolve a patent fight over Helsinn's Aloxi injection in the U.S., where it is distributed by Eisai. Release

> The Drug Enforcement Agency's (DEA) attempts at stemming painkiller abuse is falling short at pharmacies. More (sub. req.)

> Chinese hospitals have reported shortages of some cheap but essential medicines thanks to alleged monopolies on raw materials. Report

> Japan's Otsuka Pharmaceutical has lost its bid for attorney fees in an Abilify patent dispute. More (reg. req.)

Medical Device News

@FierceMedDev: ICYMI yesterday: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @FierceMedDev

@VarunSaxena2: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More | Follow @VarunSaxena2

@EmilyWFierce: Report: AstraZeneca funnels billions into Dutch tax-avoidance scheme. FiercePharma story | Follow @EmilyWFierce

> Is Turing illegally thwarting generic copycats? New York antitrust squad wants to know. More

> J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article

Biotech News

@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Analysts, experts write off Merck's huge anacetrapib PhIII. Report | Follow @JohnCFierce

@DamianFierce: Entirely baffled by 's business model. More | Follow @DamianFierce

> Zafgen shares continue to slide on market fears. Item

> Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash. Report

> FDA misses approval date for Collegium's pain drug. News

Drug Delivery News

> Study finds EpiPens can injure children, recommends improved technique and design. More

> Russian Academy: Combining drugs with ionic liquids can up the solubility, cut polymorphism. News

> Medicines Co. enters Japanese market, handing over license to transdermal pain patch. Story

> OptiNose bags $30M in VC financing as partner Otsuka barrels toward its second PDUFA date. Article

> 3M takes on blood-brain barrier with Impel Neuropharma nasal drug delivery alliance. Report

Pharma Manufacturing News

> Pests again figure into issues in FDA warning letter to Indian API maker. More

> Cipla's new U.S. plant received Form 483 just ahead of deal. News

> CPhI report predicts growth in outsourcing for sterile injectables. More

> Aurobindo to expand India API plant fourfold. Story

> Hong Kong's gray market draws mainland Chinese looking for lifesaving meds they can't afford at home. Article

Pharma Asia News

> HK-listed 3SBio inks oncology antibody drug deal with South Korea's Alteogen. Story

> CIMB says Malaysian pharmas have scope to adjust to TPP changes. Report

> China's Innovent Biologics deepens pact with Eli Lilly on immuno-oncology. Article

> Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. Item

> Hong Kong drugstores attract Chinese customers for cancer, hep C drugs. More

And Finally... Health officials and healthcare execs working to combat the rise in drug-resistant infections are training their eyes on nursing homes, where antibiotics are among the most frequently prescribed meds. More (sub. req.)

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.